<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654885</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-US-EYE-0600</org_study_id>
    <nct_id>NCT03654885</nct_id>
  </id_info>
  <brief_title>XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)</brief_title>
  <acronym>XEN GPS</acronym>
  <official_title>XEN45 Gel Stent Versus Trabeculectomy in Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness and safety of XEN to trabeculectomy in&#xD;
      subjects with open angle glaucoma refractory to topical medical therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, parallel group, prospective, open-label clinical trial to&#xD;
      evaluate the ability of XEN to reduce IOP and reduce the amount of topical IOP-lowering&#xD;
      medications in subjects poorly controlled on topical therapy. Patients will be randomized&#xD;
      2:1, resulting in approximately 190 eyes being implanted with XEN and approximately 95 eyes&#xD;
      will be receiving trabeculectomy. Subjects will be screened for enrollment and eligible&#xD;
      candidates will be approached to ascertain interest in study participation. Study duration&#xD;
      will be approximately 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">May 13, 2021</completion_date>
  <primary_completion_date type="Actual">May 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving at least 20% mean Intraocular pressure (IOP) change from baseline on the same or fewer number of IOP-lowering medications</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (medicated) in mean Intraocular pressure (IOP)</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (medicated) in mean number of topical IOP-lowering medications</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes achieving specific IOP targets (≤18 mmHg, ≤17 mmHg, ≤16 mmHg, ≤15 mmHg, ≤14 mmHg, ≤13 mmHg, ≤12 mmHg</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes achieving at least 20% IOP reductions and specific IOP targets on same or lower number of topical IOP-lowering medications</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes achieving at least 20% reduction of needling rates, number of needlings per eye, outcomes post needling, antifibrotics, including mean IOP and number of medications measured</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>XEN group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN group</intervention_name>
    <description>Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation</description>
    <arm_group_label>XEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Open-angle glaucoma where the Intraocular pressure (IOP) is not controlled when using&#xD;
             topical IOP-lowering glaucoma medication&#xD;
&#xD;
          -  Best-corrected baseline Snellen visual acuity of 20/80 or better&#xD;
&#xD;
          -  Visual field mean deviation no worse than -15.0 dB&#xD;
&#xD;
          -  Medicated IOP ≥18 mmHg and ≤44 mmHg&#xD;
&#xD;
          -  Subjects not anticipated to require any ocular surgery (e.g., cataract surgery) in&#xD;
             either eye up to 12 months from the time of inclusion&#xD;
&#xD;
          -  Area of healthy, free, and mobile conjunctiva in the target area (superior bulbar&#xD;
             conjunctiva)&#xD;
&#xD;
          -  Trabecular meshwork must be visible (with Shaffer angle grade ≥2 in the target&#xD;
             quadrant)&#xD;
&#xD;
          -  Failed ab-interno canal or suprachoroidal MIGS procedures (such as i-Stent, CyPass,&#xD;
             GATT, ABiC, Kahook dual blade goniotomy, etc.) are allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has active neovascular, uveitic or angle recession glaucoma or any glaucoma&#xD;
             associated with vascular disorders&#xD;
&#xD;
          -  Subject has had prior ab externo incisional glaucoma surgery (such as trabeculectomy,&#xD;
             viscocanalostomy, canaloplasty, tube shunts of any type, collagen implants, etc.),&#xD;
             conjunctival filtering surgery, transscleral cycloablative procedures (such as&#xD;
             cyclophotocoagulation, micro pulse cyclophotocoagulation, cryotherapy, UC3, etc.) or&#xD;
             prior major conjunctival surgery (i.e., scleral buckle)&#xD;
&#xD;
          -  Clinically significant inflammation or infection within 30 days before the&#xD;
             preoperative visit (e.g., blepharitis, conjunctivitis, severe ocular surface disease,&#xD;
             keratitis, uveitis, herpes simplex infection)&#xD;
&#xD;
          -  Presence of conjunctival scarring or prior conjunctival surgery or other conjunctival&#xD;
             pathologies (e.g., pterygium) in the target area&#xD;
&#xD;
          -  History of corneal surgery, corneal opacities, or corneal disease&#xD;
&#xD;
          -  Central corneal thickness ≤490μm or ≥620μm&#xD;
&#xD;
          -  Vitreous present in the anterior chamber&#xD;
&#xD;
          -  Aphakic - Subject has had prior intraocular surgery in either eye within ≤3 months&#xD;
             before the preoperative visit (including phacoemulsification)&#xD;
&#xD;
          -  History of complicated cataract surgery (e.g. with visual impairment, e.g. vitreous&#xD;
             loss, ACIOL, perhaps sutured IOL or scleral fixated IOL, prior CME, etc.)&#xD;
&#xD;
          -  Presence of intraocular silicone oil&#xD;
&#xD;
          -  Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization,&#xD;
             branch retinal vein occlusion, central retinal vein occlusion, geographic atrophy, or&#xD;
             other ophthalmic disease or disorder that could confound study results or impaired&#xD;
             episcleral venous drainage (e.g., Sturge-Weber or nanophthalmos, Axenfeld-Reiger, ICE,&#xD;
             etc.&#xD;
&#xD;
          -  Known or suspected allergy or sensitivity to drugs required for the protocol&#xD;
             (including anesthesia), or any of the device components (e.g., bovine or porcine&#xD;
             products, or glutaraldehyde)&#xD;
&#xD;
          -  Pregnant or nursing women and those planning a pregnancy during the study period.&#xD;
&#xD;
          -  Participation in another drug or device clinical trial concluding within 30 days&#xD;
             before the preoperative visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vold Vision /ID# 233677</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California /ID# 233692</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angeles Eye Institute /ID# 233632</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cha Medical Group Pc /Id# 233649</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grutzmacher Lewis and Sierra Inc. /ID# 233654</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver /ID# 233676</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80291-0238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital /ID# 233615</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgery Associates /ID# 233638</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Retina Center /ID# 233628</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Eye Partners /ID# 233655</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates /ID# 233575</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyrie Lee Jenkins MD Inc. /ID# 233674</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Eye Center /ID# 233631</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence /ID# 233583</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Glaucoma Specialists /ID# 233690</name>
      <address>
        <city>Reading</city>
        <state>Massachusetts</state>
        <zip>01867</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center University of Michigan health system /ID# 233651</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville /ID# 233634</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis /ID# 233599</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma associates/consultants of the capital region /ID# 233695</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eye Associates /ID# 233656</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Associates Inc /ID# 233636</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute /ID# 233595</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwick Eye Center /ID# 233691</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremer Eye Center /Id# 233642</name>
      <address>
        <city>King Of Prussia</city>
        <state>Pennsylvania</state>
        <zip>19406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute /ID# 233645</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>university of Pittsburgh /ID# 233622</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Centers for Sight,PC /ID# 233606</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Vision Associates /ID# 233644</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas /ID# 233587</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons, P.A. /ID# 233584</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates /ID# 233621</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Baylor Medical Center /ID# 233612</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vistar Eye Center /ID# 233652</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Health Dean Medical Group /ID# 233624</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Centers of Racine and Kenosha LTD /ID# 233657</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

